Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Carcinoma, Non-Small-Cell Lung
  • Histiocytosis
  • Indoles
  • Mutation
  • Neoplasms
  • Proto-Oncogene Proteins B-raf
  • Sulfonamides

abstract

  • BRAF V600 appears to be a targetable oncogene in some, but not all, nonmelanoma cancers. Preliminary vemurafenib activity was observed in non-small-cell lung cancer and in Erdheim-Chester disease and Langerhans'-cell histiocytosis. The histologic context is an important determinant of response in BRAF V600-mutated cancers. (Funded by F. Hoffmann-La Roche/Genentech; ClinicalTrials.gov number, NCT01524978.).

publication date

  • January 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4971773

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1502309

PubMed ID

  • 26287849

Additional Document Info

start page

  • 726

end page

  • 36

volume

  • 373

number

  • 8